Global RNA-Based Therapeutics and Vaccines Market Research Report 2024(Status and Outlook)
Report Overview:
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The Global RNA-Based Therapeutics and Vaccines Market Size was estimated at USD 41.99 million in 2023 and is projected to reach USD 636.13 million by 2029, exhibiting a CAGR of 57.30% during the forecast period.
This report provides a deep insight into the global RNA-Based Therapeutics and Vaccines market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global RNA-Based Therapeutics and Vaccines Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the RNA-Based Therapeutics and Vaccines market in any manner.
Global RNA-Based Therapeutics and Vaccines Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Market Segmentation (by Type)
RNA-Based Therapeutics
RNA-Based Vaccines
Market Segmentation (by Application)
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the RNA-Based Therapeutics and Vaccines Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
RNA-based biopharmaceuticals, which includes therapeutics and vaccines, is a relatively new class of treatment and prophylactic for a number of chronic and rare diseases, including cancer, diabetes, tuberculosis and certaincardiovascular conditions.
The Global RNA-Based Therapeutics and Vaccines Market Size was estimated at USD 41.99 million in 2023 and is projected to reach USD 636.13 million by 2029, exhibiting a CAGR of 57.30% during the forecast period.
This report provides a deep insight into the global RNA-Based Therapeutics and Vaccines market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global RNA-Based Therapeutics and Vaccines Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the RNA-Based Therapeutics and Vaccines market in any manner.
Global RNA-Based Therapeutics and Vaccines Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Alnylam Pharmaceuticals
Arbutus Biopharma
Arrowhead Pharmaceuticals
BioNTech
CureVac
Dicerna Pharmaceuticals
Regulus Therapeutics
Marina Biotech
MiRagen Therapeutics
Moderna Therapeutics
Quark Pharmaceuticals
Roche
Sylentis
Market Segmentation (by Type)
RNA-Based Therapeutics
RNA-Based Vaccines
Market Segmentation (by Application)
Oncology
Immunology
Ophthalmology
Cardiovascular Diseases
Infectious Diseases
Genetic Diseases
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the RNA-Based Therapeutics and Vaccines Market
- Overview of the regional outlook of the RNA-Based Therapeutics and Vaccines Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the RNA-Based Therapeutics and Vaccines Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of RNA-Based Therapeutics and Vaccines
1.2 Key Market Segments
1.2.1 RNA-Based Therapeutics and Vaccines Segment by Type
1.2.2 RNA-Based Therapeutics and Vaccines Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RNA-BASED THERAPEUTICS AND VACCINES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global RNA-Based Therapeutics and Vaccines Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RNA-BASED THERAPEUTICS AND VACCINES MARKET COMPETITIVE LANDSCAPE
3.1 Global RNA-Based Therapeutics and Vaccines Sales by Manufacturers (2019-2024)
3.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Manufacturers (2019-2024)
3.3 RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global RNA-Based Therapeutics and Vaccines Average Price by Manufacturers (2019-2024)
3.5 Manufacturers RNA-Based Therapeutics and Vaccines Sales Sites, Area Served, Product Type
3.6 RNA-Based Therapeutics and Vaccines Market Competitive Situation and Trends
3.6.1 RNA-Based Therapeutics and Vaccines Market Concentration Rate
3.6.2 Global 5 and 10 Largest RNA-Based Therapeutics and Vaccines Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RNA-BASED THERAPEUTICS AND VACCINES INDUSTRY CHAIN ANALYSIS
4.1 RNA-Based Therapeutics and Vaccines Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RNA-BASED THERAPEUTICS AND VACCINES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2019-2024)
6.3 Global RNA-Based Therapeutics and Vaccines Market Size Market Share by Type (2019-2024)
6.4 Global RNA-Based Therapeutics and Vaccines Price by Type (2019-2024)
7 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global RNA-Based Therapeutics and Vaccines Market Sales by Application (2019-2024)
7.3 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) by Application (2019-2024)
7.4 Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
8 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY REGION
8.1 Global RNA-Based Therapeutics and Vaccines Sales by Region
8.1.1 Global RNA-Based Therapeutics and Vaccines Sales by Region
8.1.2 Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region
8.2 North America
8.2.1 North America RNA-Based Therapeutics and Vaccines Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe RNA-Based Therapeutics and Vaccines Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific RNA-Based Therapeutics and Vaccines Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America RNA-Based Therapeutics and Vaccines Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa RNA-Based Therapeutics and Vaccines Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Alnylam Pharmaceuticals
9.1.1 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.1.2 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.1.4 Alnylam Pharmaceuticals Business Overview
9.1.5 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
9.1.6 Alnylam Pharmaceuticals Recent Developments
9.2 Arbutus Biopharma
9.2.1 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Basic Information
9.2.2 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Overview
9.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Market Performance
9.2.4 Arbutus Biopharma Business Overview
9.2.5 Arbutus Biopharma RNA-Based Therapeutics and Vaccines SWOT Analysis
9.2.6 Arbutus Biopharma Recent Developments
9.3 Arrowhead Pharmaceuticals
9.3.1 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.3.2 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.3.4 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
9.3.5 Arrowhead Pharmaceuticals Business Overview
9.3.6 Arrowhead Pharmaceuticals Recent Developments
9.4 BioNTech
9.4.1 BioNTech RNA-Based Therapeutics and Vaccines Basic Information
9.4.2 BioNTech RNA-Based Therapeutics and Vaccines Product Overview
9.4.3 BioNTech RNA-Based Therapeutics and Vaccines Product Market Performance
9.4.4 BioNTech Business Overview
9.4.5 BioNTech Recent Developments
9.5 CureVac
9.5.1 CureVac RNA-Based Therapeutics and Vaccines Basic Information
9.5.2 CureVac RNA-Based Therapeutics and Vaccines Product Overview
9.5.3 CureVac RNA-Based Therapeutics and Vaccines Product Market Performance
9.5.4 CureVac Business Overview
9.5.5 CureVac Recent Developments
9.6 Dicerna Pharmaceuticals
9.6.1 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.6.2 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.6.4 Dicerna Pharmaceuticals Business Overview
9.6.5 Dicerna Pharmaceuticals Recent Developments
9.7 Regulus Therapeutics
9.7.1 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.7.2 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.7.4 Regulus Therapeutics Business Overview
9.7.5 Regulus Therapeutics Recent Developments
9.8 Marina Biotech
9.8.1 Marina Biotech RNA-Based Therapeutics and Vaccines Basic Information
9.8.2 Marina Biotech RNA-Based Therapeutics and Vaccines Product Overview
9.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Product Market Performance
9.8.4 Marina Biotech Business Overview
9.8.5 Marina Biotech Recent Developments
9.9 MiRagen Therapeutics
9.9.1 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.9.2 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.9.4 MiRagen Therapeutics Business Overview
9.9.5 MiRagen Therapeutics Recent Developments
9.10 Moderna Therapeutics
9.10.1 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.10.2 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.10.4 Moderna Therapeutics Business Overview
9.10.5 Moderna Therapeutics Recent Developments
9.11 Quark Pharmaceuticals
9.11.1 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.11.2 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.11.4 Quark Pharmaceuticals Business Overview
9.11.5 Quark Pharmaceuticals Recent Developments
9.12 Roche
9.12.1 Roche RNA-Based Therapeutics and Vaccines Basic Information
9.12.2 Roche RNA-Based Therapeutics and Vaccines Product Overview
9.12.3 Roche RNA-Based Therapeutics and Vaccines Product Market Performance
9.12.4 Roche Business Overview
9.12.5 Roche Recent Developments
9.13 Sylentis
9.13.1 Sylentis RNA-Based Therapeutics and Vaccines Basic Information
9.13.2 Sylentis RNA-Based Therapeutics and Vaccines Product Overview
9.13.3 Sylentis RNA-Based Therapeutics and Vaccines Product Market Performance
9.13.4 Sylentis Business Overview
9.13.5 Sylentis Recent Developments
10 RNA-BASED THERAPEUTICS AND VACCINES MARKET FORECAST BY REGION
10.1 Global RNA-Based Therapeutics and Vaccines Market Size Forecast
10.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe RNA-Based Therapeutics and Vaccines Market Size Forecast by Country
10.2.3 Asia Pacific RNA-Based Therapeutics and Vaccines Market Size Forecast by Region
10.2.4 South America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of RNA-Based Therapeutics and Vaccines by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global RNA-Based Therapeutics and Vaccines Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of RNA-Based Therapeutics and Vaccines by Type (2025-2030)
11.1.2 Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of RNA-Based Therapeutics and Vaccines by Type (2025-2030)
11.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Application (2025-2030)
11.2.1 Global RNA-Based Therapeutics and Vaccines Sales (K Units) Forecast by Application
11.2.2 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of RNA-Based Therapeutics and Vaccines
1.2 Key Market Segments
1.2.1 RNA-Based Therapeutics and Vaccines Segment by Type
1.2.2 RNA-Based Therapeutics and Vaccines Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 RNA-BASED THERAPEUTICS AND VACCINES MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global RNA-Based Therapeutics and Vaccines Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 RNA-BASED THERAPEUTICS AND VACCINES MARKET COMPETITIVE LANDSCAPE
3.1 Global RNA-Based Therapeutics and Vaccines Sales by Manufacturers (2019-2024)
3.2 Global RNA-Based Therapeutics and Vaccines Revenue Market Share by Manufacturers (2019-2024)
3.3 RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global RNA-Based Therapeutics and Vaccines Average Price by Manufacturers (2019-2024)
3.5 Manufacturers RNA-Based Therapeutics and Vaccines Sales Sites, Area Served, Product Type
3.6 RNA-Based Therapeutics and Vaccines Market Competitive Situation and Trends
3.6.1 RNA-Based Therapeutics and Vaccines Market Concentration Rate
3.6.2 Global 5 and 10 Largest RNA-Based Therapeutics and Vaccines Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 RNA-BASED THERAPEUTICS AND VACCINES INDUSTRY CHAIN ANALYSIS
4.1 RNA-Based Therapeutics and Vaccines Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF RNA-BASED THERAPEUTICS AND VACCINES MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2019-2024)
6.3 Global RNA-Based Therapeutics and Vaccines Market Size Market Share by Type (2019-2024)
6.4 Global RNA-Based Therapeutics and Vaccines Price by Type (2019-2024)
7 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global RNA-Based Therapeutics and Vaccines Market Sales by Application (2019-2024)
7.3 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) by Application (2019-2024)
7.4 Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
8 RNA-BASED THERAPEUTICS AND VACCINES MARKET SEGMENTATION BY REGION
8.1 Global RNA-Based Therapeutics and Vaccines Sales by Region
8.1.1 Global RNA-Based Therapeutics and Vaccines Sales by Region
8.1.2 Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region
8.2 North America
8.2.1 North America RNA-Based Therapeutics and Vaccines Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe RNA-Based Therapeutics and Vaccines Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific RNA-Based Therapeutics and Vaccines Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America RNA-Based Therapeutics and Vaccines Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa RNA-Based Therapeutics and Vaccines Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Alnylam Pharmaceuticals
9.1.1 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.1.2 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.1.3 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.1.4 Alnylam Pharmaceuticals Business Overview
9.1.5 Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
9.1.6 Alnylam Pharmaceuticals Recent Developments
9.2 Arbutus Biopharma
9.2.1 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Basic Information
9.2.2 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Overview
9.2.3 Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Market Performance
9.2.4 Arbutus Biopharma Business Overview
9.2.5 Arbutus Biopharma RNA-Based Therapeutics and Vaccines SWOT Analysis
9.2.6 Arbutus Biopharma Recent Developments
9.3 Arrowhead Pharmaceuticals
9.3.1 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.3.2 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.3.3 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.3.4 Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
9.3.5 Arrowhead Pharmaceuticals Business Overview
9.3.6 Arrowhead Pharmaceuticals Recent Developments
9.4 BioNTech
9.4.1 BioNTech RNA-Based Therapeutics and Vaccines Basic Information
9.4.2 BioNTech RNA-Based Therapeutics and Vaccines Product Overview
9.4.3 BioNTech RNA-Based Therapeutics and Vaccines Product Market Performance
9.4.4 BioNTech Business Overview
9.4.5 BioNTech Recent Developments
9.5 CureVac
9.5.1 CureVac RNA-Based Therapeutics and Vaccines Basic Information
9.5.2 CureVac RNA-Based Therapeutics and Vaccines Product Overview
9.5.3 CureVac RNA-Based Therapeutics and Vaccines Product Market Performance
9.5.4 CureVac Business Overview
9.5.5 CureVac Recent Developments
9.6 Dicerna Pharmaceuticals
9.6.1 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.6.2 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.6.3 Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.6.4 Dicerna Pharmaceuticals Business Overview
9.6.5 Dicerna Pharmaceuticals Recent Developments
9.7 Regulus Therapeutics
9.7.1 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.7.2 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.7.3 Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.7.4 Regulus Therapeutics Business Overview
9.7.5 Regulus Therapeutics Recent Developments
9.8 Marina Biotech
9.8.1 Marina Biotech RNA-Based Therapeutics and Vaccines Basic Information
9.8.2 Marina Biotech RNA-Based Therapeutics and Vaccines Product Overview
9.8.3 Marina Biotech RNA-Based Therapeutics and Vaccines Product Market Performance
9.8.4 Marina Biotech Business Overview
9.8.5 Marina Biotech Recent Developments
9.9 MiRagen Therapeutics
9.9.1 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.9.2 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.9.3 MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.9.4 MiRagen Therapeutics Business Overview
9.9.5 MiRagen Therapeutics Recent Developments
9.10 Moderna Therapeutics
9.10.1 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
9.10.2 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
9.10.3 Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Market Performance
9.10.4 Moderna Therapeutics Business Overview
9.10.5 Moderna Therapeutics Recent Developments
9.11 Quark Pharmaceuticals
9.11.1 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
9.11.2 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
9.11.3 Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Market Performance
9.11.4 Quark Pharmaceuticals Business Overview
9.11.5 Quark Pharmaceuticals Recent Developments
9.12 Roche
9.12.1 Roche RNA-Based Therapeutics and Vaccines Basic Information
9.12.2 Roche RNA-Based Therapeutics and Vaccines Product Overview
9.12.3 Roche RNA-Based Therapeutics and Vaccines Product Market Performance
9.12.4 Roche Business Overview
9.12.5 Roche Recent Developments
9.13 Sylentis
9.13.1 Sylentis RNA-Based Therapeutics and Vaccines Basic Information
9.13.2 Sylentis RNA-Based Therapeutics and Vaccines Product Overview
9.13.3 Sylentis RNA-Based Therapeutics and Vaccines Product Market Performance
9.13.4 Sylentis Business Overview
9.13.5 Sylentis Recent Developments
10 RNA-BASED THERAPEUTICS AND VACCINES MARKET FORECAST BY REGION
10.1 Global RNA-Based Therapeutics and Vaccines Market Size Forecast
10.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe RNA-Based Therapeutics and Vaccines Market Size Forecast by Country
10.2.3 Asia Pacific RNA-Based Therapeutics and Vaccines Market Size Forecast by Region
10.2.4 South America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of RNA-Based Therapeutics and Vaccines by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global RNA-Based Therapeutics and Vaccines Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of RNA-Based Therapeutics and Vaccines by Type (2025-2030)
11.1.2 Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of RNA-Based Therapeutics and Vaccines by Type (2025-2030)
11.2 Global RNA-Based Therapeutics and Vaccines Market Forecast by Application (2025-2030)
11.2.1 Global RNA-Based Therapeutics and Vaccines Sales (K Units) Forecast by Application
11.2.2 Global RNA-Based Therapeutics and Vaccines Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. RNA-Based Therapeutics and Vaccines Market Size Comparison by Region (M USD)
Table 5. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Manufacturers (2019-2024)
Table 7. Global RNA-Based Therapeutics and Vaccines Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global RNA-Based Therapeutics and Vaccines Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2022)
Table 10. Global Market RNA-Based Therapeutics and Vaccines Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers RNA-Based Therapeutics and Vaccines Sales Sites and Area Served
Table 12. Manufacturers RNA-Based Therapeutics and Vaccines Product Type
Table 13. Global RNA-Based Therapeutics and Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of RNA-Based Therapeutics and Vaccines
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. RNA-Based Therapeutics and Vaccines Market Challenges
Table 22. Global RNA-Based Therapeutics and Vaccines Sales by Type (K Units)
Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Type (M USD)
Table 24. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Type (2019-2024)
Table 25. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2019-2024)
Table 26. Global RNA-Based Therapeutics and Vaccines Market Size (M USD) by Type (2019-2024)
Table 27. Global RNA-Based Therapeutics and Vaccines Market Size Share by Type (2019-2024)
Table 28. Global RNA-Based Therapeutics and Vaccines Price (USD/Unit) by Type (2019-2024)
Table 29. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Application
Table 30. Global RNA-Based Therapeutics and Vaccines Market Size by Application
Table 31. Global RNA-Based Therapeutics and Vaccines Sales by Application (2019-2024) & (K Units)
Table 32. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2019-2024)
Table 33. Global RNA-Based Therapeutics and Vaccines Sales by Application (2019-2024) & (M USD)
Table 34. Global RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2024)
Table 35. Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
Table 36. Global RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 37. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region (2019-2024)
Table 38. North America RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 39. Europe RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 41. South America RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 43. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 44. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 45. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Alnylam Pharmaceuticals Business Overview
Table 47. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 48. Alnylam Pharmaceuticals Recent Developments
Table 49. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Basic Information
Table 50. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Overview
Table 51. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Arbutus Biopharma Business Overview
Table 53. Arbutus Biopharma RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 54. Arbutus Biopharma Recent Developments
Table 55. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 56. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 57. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 59. Arrowhead Pharmaceuticals Business Overview
Table 60. Arrowhead Pharmaceuticals Recent Developments
Table 61. BioNTech RNA-Based Therapeutics and Vaccines Basic Information
Table 62. BioNTech RNA-Based Therapeutics and Vaccines Product Overview
Table 63. BioNTech RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. BioNTech Business Overview
Table 65. BioNTech Recent Developments
Table 66. CureVac RNA-Based Therapeutics and Vaccines Basic Information
Table 67. CureVac RNA-Based Therapeutics and Vaccines Product Overview
Table 68. CureVac RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. CureVac Business Overview
Table 70. CureVac Recent Developments
Table 71. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 72. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 73. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Dicerna Pharmaceuticals Business Overview
Table 75. Dicerna Pharmaceuticals Recent Developments
Table 76. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 77. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 78. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Regulus Therapeutics Business Overview
Table 80. Regulus Therapeutics Recent Developments
Table 81. Marina Biotech RNA-Based Therapeutics and Vaccines Basic Information
Table 82. Marina Biotech RNA-Based Therapeutics and Vaccines Product Overview
Table 83. Marina Biotech RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Marina Biotech Business Overview
Table 85. Marina Biotech Recent Developments
Table 86. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 87. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 88. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. MiRagen Therapeutics Business Overview
Table 90. MiRagen Therapeutics Recent Developments
Table 91. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 92. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 93. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Moderna Therapeutics Business Overview
Table 95. Moderna Therapeutics Recent Developments
Table 96. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 97. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 98. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Quark Pharmaceuticals Business Overview
Table 100. Quark Pharmaceuticals Recent Developments
Table 101. Roche RNA-Based Therapeutics and Vaccines Basic Information
Table 102. Roche RNA-Based Therapeutics and Vaccines Product Overview
Table 103. Roche RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Roche Business Overview
Table 105. Roche Recent Developments
Table 106. Sylentis RNA-Based Therapeutics and Vaccines Basic Information
Table 107. Sylentis RNA-Based Therapeutics and Vaccines Product Overview
Table 108. Sylentis RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Sylentis Business Overview
Table 110. Sylentis Recent Developments
Table 111. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 112. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2025-2030) & (M USD)
Table 113. North America RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 114. North America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 115. Europe RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 116. Europe RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 117. Asia Pacific RNA-Based Therapeutics and Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 118. Asia Pacific RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2025-2030) & (M USD)
Table 119. South America RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 120. South America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa RNA-Based Therapeutics and Vaccines Consumption Forecast by Country (2025-2030) & (Units)
Table 122. Middle East and Africa RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 123. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Type (2025-2030) & (K Units)
Table 124. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Type (2025-2030) & (M USD)
Table 125. Global RNA-Based Therapeutics and Vaccines Price Forecast by Type (2025-2030) & (USD/Unit)
Table 126. Global RNA-Based Therapeutics and Vaccines Sales (K Units) Forecast by Application (2025-2030)
Table 127. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. RNA-Based Therapeutics and Vaccines Market Size Comparison by Region (M USD)
Table 5. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Manufacturers (2019-2024)
Table 7. Global RNA-Based Therapeutics and Vaccines Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global RNA-Based Therapeutics and Vaccines Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNA-Based Therapeutics and Vaccines as of 2022)
Table 10. Global Market RNA-Based Therapeutics and Vaccines Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers RNA-Based Therapeutics and Vaccines Sales Sites and Area Served
Table 12. Manufacturers RNA-Based Therapeutics and Vaccines Product Type
Table 13. Global RNA-Based Therapeutics and Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of RNA-Based Therapeutics and Vaccines
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. RNA-Based Therapeutics and Vaccines Market Challenges
Table 22. Global RNA-Based Therapeutics and Vaccines Sales by Type (K Units)
Table 23. Global RNA-Based Therapeutics and Vaccines Market Size by Type (M USD)
Table 24. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Type (2019-2024)
Table 25. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Type (2019-2024)
Table 26. Global RNA-Based Therapeutics and Vaccines Market Size (M USD) by Type (2019-2024)
Table 27. Global RNA-Based Therapeutics and Vaccines Market Size Share by Type (2019-2024)
Table 28. Global RNA-Based Therapeutics and Vaccines Price (USD/Unit) by Type (2019-2024)
Table 29. Global RNA-Based Therapeutics and Vaccines Sales (K Units) by Application
Table 30. Global RNA-Based Therapeutics and Vaccines Market Size by Application
Table 31. Global RNA-Based Therapeutics and Vaccines Sales by Application (2019-2024) & (K Units)
Table 32. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2019-2024)
Table 33. Global RNA-Based Therapeutics and Vaccines Sales by Application (2019-2024) & (M USD)
Table 34. Global RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2024)
Table 35. Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
Table 36. Global RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 37. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region (2019-2024)
Table 38. North America RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 39. Europe RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 41. South America RNA-Based Therapeutics and Vaccines Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales by Region (2019-2024) & (K Units)
Table 43. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 44. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 45. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Alnylam Pharmaceuticals Business Overview
Table 47. Alnylam Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 48. Alnylam Pharmaceuticals Recent Developments
Table 49. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Basic Information
Table 50. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Product Overview
Table 51. Arbutus Biopharma RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Arbutus Biopharma Business Overview
Table 53. Arbutus Biopharma RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 54. Arbutus Biopharma Recent Developments
Table 55. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 56. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 57. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Arrowhead Pharmaceuticals RNA-Based Therapeutics and Vaccines SWOT Analysis
Table 59. Arrowhead Pharmaceuticals Business Overview
Table 60. Arrowhead Pharmaceuticals Recent Developments
Table 61. BioNTech RNA-Based Therapeutics and Vaccines Basic Information
Table 62. BioNTech RNA-Based Therapeutics and Vaccines Product Overview
Table 63. BioNTech RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. BioNTech Business Overview
Table 65. BioNTech Recent Developments
Table 66. CureVac RNA-Based Therapeutics and Vaccines Basic Information
Table 67. CureVac RNA-Based Therapeutics and Vaccines Product Overview
Table 68. CureVac RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. CureVac Business Overview
Table 70. CureVac Recent Developments
Table 71. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 72. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 73. Dicerna Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Dicerna Pharmaceuticals Business Overview
Table 75. Dicerna Pharmaceuticals Recent Developments
Table 76. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 77. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 78. Regulus Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Regulus Therapeutics Business Overview
Table 80. Regulus Therapeutics Recent Developments
Table 81. Marina Biotech RNA-Based Therapeutics and Vaccines Basic Information
Table 82. Marina Biotech RNA-Based Therapeutics and Vaccines Product Overview
Table 83. Marina Biotech RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Marina Biotech Business Overview
Table 85. Marina Biotech Recent Developments
Table 86. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 87. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 88. MiRagen Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. MiRagen Therapeutics Business Overview
Table 90. MiRagen Therapeutics Recent Developments
Table 91. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Basic Information
Table 92. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Product Overview
Table 93. Moderna Therapeutics RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Moderna Therapeutics Business Overview
Table 95. Moderna Therapeutics Recent Developments
Table 96. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Basic Information
Table 97. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Product Overview
Table 98. Quark Pharmaceuticals RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Quark Pharmaceuticals Business Overview
Table 100. Quark Pharmaceuticals Recent Developments
Table 101. Roche RNA-Based Therapeutics and Vaccines Basic Information
Table 102. Roche RNA-Based Therapeutics and Vaccines Product Overview
Table 103. Roche RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Roche Business Overview
Table 105. Roche Recent Developments
Table 106. Sylentis RNA-Based Therapeutics and Vaccines Basic Information
Table 107. Sylentis RNA-Based Therapeutics and Vaccines Product Overview
Table 108. Sylentis RNA-Based Therapeutics and Vaccines Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Sylentis Business Overview
Table 110. Sylentis Recent Developments
Table 111. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 112. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2025-2030) & (M USD)
Table 113. North America RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 114. North America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 115. Europe RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 116. Europe RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 117. Asia Pacific RNA-Based Therapeutics and Vaccines Sales Forecast by Region (2025-2030) & (K Units)
Table 118. Asia Pacific RNA-Based Therapeutics and Vaccines Market Size Forecast by Region (2025-2030) & (M USD)
Table 119. South America RNA-Based Therapeutics and Vaccines Sales Forecast by Country (2025-2030) & (K Units)
Table 120. South America RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa RNA-Based Therapeutics and Vaccines Consumption Forecast by Country (2025-2030) & (Units)
Table 122. Middle East and Africa RNA-Based Therapeutics and Vaccines Market Size Forecast by Country (2025-2030) & (M USD)
Table 123. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Type (2025-2030) & (K Units)
Table 124. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Type (2025-2030) & (M USD)
Table 125. Global RNA-Based Therapeutics and Vaccines Price Forecast by Type (2025-2030) & (USD/Unit)
Table 126. Global RNA-Based Therapeutics and Vaccines Sales (K Units) Forecast by Application (2025-2030)
Table 127. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of RNA-Based Therapeutics and Vaccines
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global RNA-Based Therapeutics and Vaccines Market Size (M USD), 2019-2030
Figure 5. Global RNA-Based Therapeutics and Vaccines Market Size (M USD) (2019-2030)
Figure 6. Global RNA-Based Therapeutics and Vaccines Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. RNA-Based Therapeutics and Vaccines Market Size by Country (M USD)
Figure 11. RNA-Based Therapeutics and Vaccines Sales Share by Manufacturers in 2023
Figure 12. Global RNA-Based Therapeutics and Vaccines Revenue Share by Manufacturers in 2023
Figure 13. RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market RNA-Based Therapeutics and Vaccines Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global RNA-Based Therapeutics and Vaccines Market Share by Type
Figure 18. Sales Market Share of RNA-Based Therapeutics and Vaccines by Type (2019-2024)
Figure 19. Sales Market Share of RNA-Based Therapeutics and Vaccines by Type in 2023
Figure 20. Market Size Share of RNA-Based Therapeutics and Vaccines by Type (2019-2024)
Figure 21. Market Size Market Share of RNA-Based Therapeutics and Vaccines by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global RNA-Based Therapeutics and Vaccines Market Share by Application
Figure 24. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2019-2024)
Figure 25. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application in 2023
Figure 26. Global RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2024)
Figure 27. Global RNA-Based Therapeutics and Vaccines Market Share by Application in 2023
Figure 28. Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
Figure 29. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region (2019-2024)
Figure 30. North America RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 32. U.S. RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada RNA-Based Therapeutics and Vaccines Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico RNA-Based Therapeutics and Vaccines Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 37. Germany RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 43. Asia Pacific RNA-Based Therapeutics and Vaccines Sales Market Share by Region in 2023
Figure 44. China RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 50. South America RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 51. Brazil RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales Market Share by Region in 2023
Figure 56. Saudi Arabia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global RNA-Based Therapeutics and Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Type (2025-2030)
Figure 65. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Application (2025-2030)
Figure 66. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of RNA-Based Therapeutics and Vaccines
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global RNA-Based Therapeutics and Vaccines Market Size (M USD), 2019-2030
Figure 5. Global RNA-Based Therapeutics and Vaccines Market Size (M USD) (2019-2030)
Figure 6. Global RNA-Based Therapeutics and Vaccines Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. RNA-Based Therapeutics and Vaccines Market Size by Country (M USD)
Figure 11. RNA-Based Therapeutics and Vaccines Sales Share by Manufacturers in 2023
Figure 12. Global RNA-Based Therapeutics and Vaccines Revenue Share by Manufacturers in 2023
Figure 13. RNA-Based Therapeutics and Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market RNA-Based Therapeutics and Vaccines Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by RNA-Based Therapeutics and Vaccines Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global RNA-Based Therapeutics and Vaccines Market Share by Type
Figure 18. Sales Market Share of RNA-Based Therapeutics and Vaccines by Type (2019-2024)
Figure 19. Sales Market Share of RNA-Based Therapeutics and Vaccines by Type in 2023
Figure 20. Market Size Share of RNA-Based Therapeutics and Vaccines by Type (2019-2024)
Figure 21. Market Size Market Share of RNA-Based Therapeutics and Vaccines by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global RNA-Based Therapeutics and Vaccines Market Share by Application
Figure 24. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application (2019-2024)
Figure 25. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Application in 2023
Figure 26. Global RNA-Based Therapeutics and Vaccines Market Share by Application (2019-2024)
Figure 27. Global RNA-Based Therapeutics and Vaccines Market Share by Application in 2023
Figure 28. Global RNA-Based Therapeutics and Vaccines Sales Growth Rate by Application (2019-2024)
Figure 29. Global RNA-Based Therapeutics and Vaccines Sales Market Share by Region (2019-2024)
Figure 30. North America RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 32. U.S. RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada RNA-Based Therapeutics and Vaccines Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico RNA-Based Therapeutics and Vaccines Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 37. Germany RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 43. Asia Pacific RNA-Based Therapeutics and Vaccines Sales Market Share by Region in 2023
Figure 44. China RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 50. South America RNA-Based Therapeutics and Vaccines Sales Market Share by Country in 2023
Figure 51. Brazil RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa RNA-Based Therapeutics and Vaccines Sales Market Share by Region in 2023
Figure 56. Saudi Arabia RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa RNA-Based Therapeutics and Vaccines Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global RNA-Based Therapeutics and Vaccines Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global RNA-Based Therapeutics and Vaccines Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Type (2025-2030)
Figure 65. Global RNA-Based Therapeutics and Vaccines Sales Forecast by Application (2025-2030)
Figure 66. Global RNA-Based Therapeutics and Vaccines Market Share Forecast by Application (2025-2030)
